Amalia Leceta (1), Ander Sologuren (2), Román Valiente (2), Cristina Campo (2), Luis Labeaga (1)
(1)Medical Department, Faes Farma SA, 48940-Leioa, Bizkaia, Spain; (2)Clinical Research Department, Faes Farma SA, 48940-Leioa, Bizkaia, Spain
(1)Medical Department, Faes Farma SA, 48940-Leioa, Bizkaia, Spain; (2)Clinical Research Department, Faes Farma SA, 48940-Leioa, Bizkaia, Spain
Bilastine is a safe and effective commonly prescribed non-sedating H1-antihistamine approved for symptomatic treatment in patients with allergic disorders such as rhinoconjunctivitis and urticaria.
It was evaluated in many patients throughout the clinical development required for its approval, but clinical trials generally exclude many patients who will benefit in everyday clinical practice (especially those with coexisting diseases and/or being treated with concomitant drugs).
Following its introduction into clinical practice, the Medical Information Specialists at Faes Farma have received many practical queries regarding the optimal use of bilastine in different circumstances.
